12 April 2021 | News
GenScript, Parkway Laboratories and Diagnostics Development (DxD) Hub announce collaboration
Image credit- prnewswire
GenScript Biotech Corporation, Parkway Laboratories and the Diagnostics Development (DxD) Hub announced their collaboration to provide the cPass™ SARS-CoV-2 neutralizing antibody test in Singapore through Parkway's panel of specialist and GP clinics.
Neutralizing antibodies are a small percentage of antibodies that bind to sites on the virus and inhibit entry of that virus into the host. Unlike the many COVID-19 lab-based antibody test kits commercially available, cPass™ can detect functional neutralizing antibodies.
Traditionally, measuring neutralizing antibodies requires the use of live virus, cells, highly skilled operators, and complex laboratory procedures that require several days in the laboratory to obtain results and limit their widespread use.
In contrast, the cPass™ kit can be performed in most standard laboratories with a short turnaround time (approx. 1hr). cPass™ is also adaptable to high throughput and fully automated testing.
The cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit was co-developed by Duke-NUS Medical School (Duke-NUS), a research-intensive graduate-entry medical school, GenScript, and DxD Hub.
The kit has received provisional authorization by the Health Sciences Authority (HSA) Singapore, CE-IVD marking in Europe and emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA).